By comparing cytotoxicity measured by the area under the curve (AUC) of 265 investigational and accepted compounds in pSTAT3 high (n = 27) and low (n = 583) cancer cell lines reported in the Sanger GDSC and CCLE databases respectively, we identified the JAK-STAT inhibitor ruxolitinib to be more potent in pSTAT3 high cell lines (Figure 7). Here, SOAT1 is linked to cancer.